ArticleCanadian journal of gastroenterology & hepatology2026
Clinical Evaluation of a Stool-Based Molecular Point-of-Care Test Kit for Noninvasive Detection of Helicobacter pylori Infection and Clarithromycin Resistance.
Article in Canadian journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Evaluation of a Stool-Based Molecular Point-of-Care Test Kit for Noninvasive Detection of Helicobacter pylori Infection and Clarithromycin Resistance.Canadian journal of gastroenterology & hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimAlthough molecular point-of-care testing using intragastric fluid has improved the speed and accuracy of Helicobacter pylori (H. pylori) diagnosis and clarithromycin (CAM) resistance detection, it still requires endoscopy, which limits its application in routine screening and settings where invasive procedures cannot be performed. We aimed to evaluate the clinical performance of the Smart Gene™ molecular point-of-care testing kit using stool specimens for H. pylori infection and CAM resistance detection.
methodsWe used stool specimens from 75 patients with suspected H. pylori infection. All participants underwent conventional diagnostic tests (urea breath test, stool antigen test, culture, and real-time polymerase chain reaction). CAM resistance-associated mutations (Positions 2142 and 2143 in the 23S rRNA gene) were analyzed using pyrosequencing.
resultsThe stool-based Smart Gene kit demonstrated a sensitivity of 96.1% and specificity of 100% for H. pylori detection. The sensitivity and specificity for detecting CAM resistance were 100% and 97.0%, respectively, compared to antibiotic susceptibility testing. High concordance was observed between the intragastric polymerase chain reaction and culture results despite the lower stool DNA concentration. The results were obtained within approximately 1 h.
conclusionsThe Smart Gene™ stool kit offers a rapid, accurate, and noninvasive alternative for diagnosing H. pylori infection and CAM resistance. Its diagnostic performance is comparable to that of the gold-standard invasive methods while offering practical advantages for outpatient use, mass screening, and nonendoscopy-feasible populations. This approach increases early H. pylori detection and improves eradication outcomes and contributes to more effective gastric cancer prevention strategies (approval number: R4-0426001).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.